Most biotech web design projects run into trouble long before anyone chooses a colour or a layout, and that holds whether you are building a first website or planning a redesign. The problems start in the planning: an unclear idea of who the site is for, no agreement on the single job it needs to do, and a pile of content that was never audited. Planning a biotech web design project well means settling those questions first, defining the primary audience, the site’s main goal, the content and evidence you already hold, and the technical requirements, so that the design decisions have something real to serve. This guide sets out how to plan that work, for a new build or an update, before you write a brief or approach a team.
Key takeaway: A biotech web design project, whether a new build or a redesign, succeeds or fails on the decisions made before the build, not on the visual design that follows.
Good biotech web design starts by naming who the site is really for
A biotech website usually serves several audiences at once, and the planning has to decide which one comes first. Investors reviewing you during a raise, scientific buyers evaluating an instrument or an assay, potential partners running diligence, and prospective hires all read the same pages differently. A site built to impress investors can lose the scientist comparing your method against a competitor, and a site written only for scientists can leave a partner unsure whether you are a business or a lab. On a redesign this matters even more, because the audience has often shifted since the last build: a company that was grant-funded may now be investor-facing, or one with a single assay may now sell a product line. Naming the primary audience, and the decision that audience is trying to make, is the first planning task, because it settles what the homepage leads with. This is also where a site connects to your wider positioning and messaging, since the audience you prioritise shapes the language the whole site uses.
What should a biotech website actually do?
A biotech website should do one primary job well, and the plan is where you decide what that job is. For some companies the main job is credibility, so a partner or investor checks that you exist and takes you seriously. For others it is enquiry generation, so a scientific buyer requests a quote or downloads an application note. For a company mid-raise, it is investor readiness. A site attempting all three with equal weight tends to do none of them convincingly. On a redesign, the sharper version of this question is what the current site fails to do, so name the specific gap, whether that is weak enquiry flow, dated positioning, or content no buyer can find, before you rebuild. Either way, the planning stage picks the primary job and a way to measure it, so the design is built around an outcome rather than decorated around a home page.
A website cannot resolve a decision about audience and purpose that the company has not made for itself.
Most of the planning work is content, not design
The largest part of planning a biotech web design project is deciding what content exists, what is missing, and what has to be created. Biotechnology companies usually hold more raw material than they realise: publications, application notes, assay data, technical validation, conference posters, and team credentials. Much of it was written for scientists and needs reframing for a commercial reader without losing accuracy. On a redesign, the audit also runs over the current site page by page, deciding what to keep, rewrite, merge, or retire, and which URLs must be preserved or redirected so the search visibility you have built up is not lost in the move. For science companies the list often differs again: a scientific instrument company or a CRO needs workflow diagrams, method detail, and procurement information that a therapeutics company does not. Getting the content plan wrong is the most common reason a build slips, because design cannot proceed around pages that have no words yet. Treating the site as a content asset rather than a brochure changes what you plan for.
Strategy note: On a redesign, a page-by-page audit of what to keep, cut, or rewrite stops you rebuilding weak content in a nicer template, which is how a refresh ends up looking new while performing the same.
A planning sequence to follow before you brief a biotech web design agency
Planning a biotech web design project follows a clear order, whether you are starting fresh or reworking an existing site, because each decision narrows the next. Settle the audience before the job, the job before the content, and the content before the structure, and the brief almost writes itself.
Web design planning sequence: work through these six decisions in order, since each one constrains the choices that follow.
- Define the primary audience and the decision they are trying to make.
- Fix the site’s main job, and the measure that will tell you it worked.
- Audit the content and evidence you hold, including the current site on a redesign, and list what to create, keep, rewrite, or retire.
- Map the site structure to the buyer’s journey rather than your internal org chart.
- Set the technical and measurement requirements: performance, mobile, accessibility, and analytics.
- Write the brief, so scope is agreed up front rather than discovered mid-build.
Step five is worth specifying early. Google’s own page experience guidance treats loading performance, mobile-friendliness, and visual stability as part of how it assesses pages, and these are far cheaper to build in from the start than to retrofit onto a finished site. On a redesign they are also among the easiest gains to lose, so name them in the brief and hold the finished biotech website design to a standard rather than a feeling.
What changes when you are redesigning rather than starting fresh
Redesigning an existing biotech website adds decisions a new build never faces, and skipping them is where redesigns quietly go wrong. You inherit content, URLs, analytics history, and whatever search visibility the current site has earned, which is an advantage a blank page does not have: you can see which pages draw traffic, which generate enquiries, and where visitors leave, and plan from that evidence rather than a guess. The same inheritance carries risk. Dropping or re-slugging pages that already rank can lose visibility overnight, so a redesign plan has to map redirects before anything moves. It is also worth separating a strategic redesign, where the audience or the positioning has genuinely changed, from a cosmetic refresh, where the site only looks dated, because the two need very different planning depth. A redesign is the moment to clear structural debt, not to rebuild it more attractively.
The plan changes depending on the kind of life science company you are
The right web design plan for a biotech therapeutics company is not the right plan for a scientific instrument company or a CRO, and that is true for a new build and a redesign alike. The audience differs, the decision the site has to support differs, and the evidence that carries weight differs, so the planning has to start from the company type rather than a template.
| Company type | Primary audience | Main job of the site | Evidence that carries weight |
|---|---|---|---|
| Biotech (therapeutics) | Investors and partners | Signal credibility and fundability | Pipeline, team, publications, differentiation |
| Scientific instrument company | Scientific buyers and procurement | Support evaluation and generate enquiries | Application notes, specifications, workflow fit |
| CRO or CDMO | BD leads and study sponsors | Build trust and show capability | Service scope, accreditations, method detail |
| Diagnostics company | Clinicians, labs, and payers | Explain use and validation | Validation data, regulatory status, workflow |
Planning is what makes a biotech web design project deliver
A biotech web design project delivers when the planning has already answered who the site is for, what it must achieve, and what content stands behind it, and that is as true for a redesign as for a first build. The build then becomes execution rather than negotiation, and the design work is judged against decisions everyone has agreed rather than opinions raised late. Whether you are starting fresh or updating an existing site, the sequence holds: decide the audience, fix the job, audit the content, map the structure, set the technical bar, then brief. A well-planned biotech website, a biopharma web design project, or a life science site of any kind all start from that same discipline, and it is the part no amount of visual polish can replace.
Planning a new site or a redesign and want a second view on the brief? Biond helps biotech and life science companies scope websites around the audience and the job before any design begins, so the build starts from decisions rather than assumptions.
Frequently Asked Questions
Biond usually recommends spending a few focused weeks on planning before a biotech web design project moves into design, whether it is a new build or a redesign. That time covers agreeing the primary audience, fixing the site’s main job, auditing existing content, and drafting the brief. Rushing this stage is the most common reason a build overruns, because design cannot proceed around decisions that have not been made.
Biond’s view is that a brief for biotech website design should state the primary audience, the site’s main goal and how it will be measured, the sitemap, the content that already exists versus what must be created, and the technical requirements. A brief that agrees scope up front prevents the mid-build changes that inflate cost and timelines for website design for biotech companies of any size.
Biond generally advises a redesign when the current biotech website still holds useful content and search visibility worth preserving, and a full rebuild only when the structure, platform, or positioning has moved too far to salvage. The decision starts from an audit of what the existing site earns and where it fails. That evidence settles the question more reliably than how dated the site happens to look.
Biond plans web design differently for each, because a scientific instrument company, a CRO or CDMO, and a diagnostics firm serve different buyers and different decisions. An instrument company’s site supports evaluation and procurement with application notes and workflow detail, a CRO builds trust through capability and accreditation, and a diagnostics firm leads with validation and regulatory status. The planning starts from that audience, not a shared template.
Biond thinks most biotech and life science companies can do the planning themselves, and often should, since it forces internal agreement on audience and purpose. An outside partner helps most when the internal team lacks the time or wants an independent read on structure, content, and the brief. Whether the build is handled in-house or by a biotech web design agency, the planning sequence stays the same.